Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 8213 results

  1. O2Matic pro 100 (MT746)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  2. Subcutaneous pembrolizumab with platinum-based chemotherapy for untreated metastatic non-small-cell lung cancer [TSID12213]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Oral cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12214]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Long-acting injections of cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12219]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    In development Reference number: GID-TA11094 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. NY-ESO-1 T-cells for treating synovial sarcoma ID1286

    In development Reference number: GID-TA10205 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development Reference number: GID-TA10248 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

    In development Reference number: GID-TA10249 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development Reference number: GID-TA10250 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development Reference number: GID-TA10251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Awaiting development Reference number: GID-HST10022 Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development